Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, has announced the launch of BaseMap ABE.
Built on the Company's INDUCE-seq technology, BaseMap ABE extends the platform's capabilities to support adenine base editing (ABE) applications.
Base editing is rapidly gaining momentum as a powerful therapeutic tool that enables precise single-base genomic changes.
However, as therapeutic programmes increasingly adopt ABE, researchers require reproducible and standardised methods to comprehensively characterise unintended off-target editing events.
Unlike prediction-based approaches, BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with a clear understanding of editor specificity under physiologically relevant conditions.
The platform enables rapid, unbiased identification of off-target events, while generating standardised and robust data to support guide optimisation, editor selection and preclinical decision-making.
BaseMap ABE represents the first phase of Broken String Biosciences’ expansion into base-editing applications, building on its established INDUCE-seq technology.
Through the Early Access Programme, the company will collaborate closely with researchers developing genome editing therapies, providing first-hand experience for early adopters and generating feedback to inform future product development.
Terry Pizzie, CEO, Broken String Biosciences (pictured), said: “As gene editing technologies evolve, researchers need to understand where and how frequently off-target editing occurs."
"By extending our product portfolio to support ABE, Broken String is enabling scientists to characterise editing outcomes for one of the most promising next-generation editing modalities."
"We are excited to get this solution into the hands of early adopters – working closely with them to shape the future of our product and support the development of safe and effective base editing therapeutics.”
